RXRX

4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

Salt Lake City, April 07, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in the following upcoming investor conferences: 25th Annual Needham Virtual Healthcare Conference - Monday, April 13, 2026 Bank of America Health Care Conference 2026 - Tuesday, May 12, 2026 Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com.About RecursionRecursion (NASDAQ:RXRX) is a clinical-stage TechBio company decoding biology to radically improve lives. Recursion is advancing a portfolio of differentiated investigational med

4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

NEW YORK and SALT LAKE CITY, March 31, 2026 (GLOBE NEWSWIRE) -- Citeline, a leader in clinical solutions for the life sciences industry, today announced an expanded strategic partnership with Recursion (NASDAQ:RXRX), a leading tech-bio company decoding biology through advanced data science and automation. Recursion's end-to-end platform is designed to connect discovery through development by integrating proprietary multimodal datasets, purpose-built AI models, and experimental biology. The addition of Citeline's real-world data and evidence capabilities strengthens this foundation, enabling more precise trial design, improved site selection, and faster, more informed development decisions

SCHEDULE 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

8-K - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)

4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

Salt Lake City, UT, March 25, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Vicki Goodman, M.D., will become Recursion's Chief Medical Officer effective April 6, 2026 as David Mauro, M.D., Ph.D. transitions out of the role. As Recursion advances its pipeline and prepares for key clinical and regulatory milestones, which are consistent with previously communicated expectations, Dr. Goodman brings a rare and differentiated perspective of how to translate scientific promise into successful clinical programs. Her experience spans executive roles in biotech and large pharma, with p

4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

DENVER, March 16, 2026 (GLOBE NEWSWIRE) -- When Jensen Huang talks about the future of technology, markets tend to listen. After leading NVIDIA (NASDAQ:NVDA) to become one of the most valuable companies in the world during the AI boom, Huang is now pointing to the next technological wave: digital biology. As he recently put it, "Where do I think that the next amazing revolution is going to come? And this is going to be flat-out one of the biggest ones ever… And there's no question that digital biology is going to be it." For Huang, the idea is simple but profound. Biology is becoming programmable. Instead of treating biology as a slow-moving experimental science, artificial intelligence

4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher Gibson, Ph.D., to PacBio's Board of Directors. Dr. Gibson is the co-founder and Chairman of the Board of Directors of Recursion (NASDAQ:RXRX), a clinical-stage biotechnology company that has built one of the industry's most advanced AI-driven drug discovery platforms. Under his leadership, Recursion integrated large-scale biological data generation with machine learning to industrialize the discovery process, building a vertically integrated technology stack spanning automation, high-dimensional b

4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

DENVER, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Markets are opening with a strong crosscurrent of AI-powered drug discovery, cross-border biologics distribution, and capital structure resets. From micro-cap transformation stories to cash-rich TechBio platforms, this morning's tape highlights companies positioning for scale in 2026 and beyond. Totaligent Targets APAC Biologics and Medical Tourism Totaligent (OTCID: TGNT) announced the execution of a binding Letter of Intent (LOI) with GloMed Solutions Limited Liability Company, a Japanese medical aesthetics and biologics distributor, to form a joint venture integrating Totaligent's recently announced Aetherium Medical platform. The agreement e

S-8 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)

424B5 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)

10-K - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)

8-K - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple clinical and preclinical programs advancing with defined milestonesAchieved fifth program milestone with Sanofi, totaling $134 million in payments to date; five Recursion discovery program packages have been accepted to date, establishing a growing joint portfolio of novel AI-driven small molecules for immunology and oncology$754 million of cash and cash equivalents; exceeded original cost savings guidance and now expect runway into early 2028 without additional financing, reflecting disciplined capita

Salt Lake City, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following upcoming investor conferences: TD Cowen 46th Annual Healthcare Conference - Monday, March 2, 2026 Leerink Partners 2026 Global Healthcare Conference - Monday, March 9, 2026Jefferies 2026 Biotech on the Beach Summit — Wednesday, March 11, 2026KeyBanc 2026 Healthcare Forum — Tuesday, March 17, 2026 Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com.About RecursionRecursion (NASDAQ:RXRX) is a clinical stage TechBio co

4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)